BioPharma Credit

BioPharma Credit EBIT

The EBIT of BioPharma Credit (BPCR.L) as of Nov 21, 2026 is 129.85 M USD. In the previous year, EBIT was 122.18 M USD — a change of 6.28% (higher).

EBIT

129.85 MUSD

YoY

6.28%

Last updated:

In 2025, BioPharma Credit's EBIT was 129.85 M USD, a 6.28% increase from the 122.18 M USD EBIT recorded in the previous year.

The BioPharma Credit EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2018
70.15 M USD
Jan 1, 2019
122.33 M USD
Jan 1, 2020
89.14 M USD
Jan 1, 2021
84.96 M USD
Jan 1, 2022
182.31 M USD
Jan 1, 2023
108.45 M USD
Jan 1, 2024
122.18 M USD
Jan 1, 2025
129.85 M USD
The BioPharma Credit EBIT history
YEAREBITYoY
129.85 MUSD+6.28%
122.18 MUSD+12.66%
108.45 MUSD-40.51%
182.31 MUSD+114.59%
84.96 MUSD-4.69%
89.14 MUSD-27.13%
122.33 MUSD+74.38%
70.15 MUSD+158.63%
27.12 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioPharma Credit Revenue

BioPharma Credit Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
78.72 M USD
70.15 M USD
70.15 M USD
Jan 1, 2019
124.12 M USD
122.33 M USD
122.33 M USD
Jan 1, 2020
91.35 M USD
89.14 M USD
89.14 M USD
Jan 1, 2021
87.97 M USD
84.96 M USD
84.96 M USD
Jan 1, 2022
184.25 M USD
182.31 M USD
182.31 M USD
Jan 1, 2023
159.68 M USD
108.45 M USD
108.45 M USD
Jan 1, 2024
124.46 M USD
122.18 M USD
122.18 M USD
Jan 1, 2025
140.23 M USD
129.85 M USD
129.89 M USD

BioPharma Credit Margins

BioPharma Credit stock margins

The BioPharma Credit margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioPharma Credit. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioPharma Credit.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
76.42 %
89.11 %
89.11 %
Jan 1, 2019
100.00 %
98.56 %
98.56 %
Jan 1, 2020
100.00 %
97.57 %
97.57 %
Jan 1, 2021
100.00 %
96.58 %
96.58 %
Jan 1, 2022
100.00 %
98.95 %
98.95 %
Jan 1, 2023
69.19 %
67.92 %
67.92 %
Jan 1, 2024
100.00 %
98.17 %
98.17 %
Jan 1, 2025
81.65 %
92.60 %
92.62 %

BioPharma Credit Stock analysis

What does BioPharma Credit do? BioPharma Credit PLC was founded in 2017 and is an investment company specializing in financing in the biopharmaceutical and medical field. The company's goal is to identify investment opportunities in the rapidly growing biopharmaceutical market and generate lucrative returns for investors. BioPharma Credit's business model is based on providing loans to biotechnology and pharmaceutical companies. These loans are used to finance important projects and research that contribute to the development of new drugs and treatment methods. In return, the companies receive interest payments and loan repayments according to the agreements in the contract. BioPharma Credit pursues a differentiated strategy and invests in various sectors of the biopharmaceutical industry, such as cancer treatments, immunotherapies, or rare diseases. This includes riskier but potentially very profitable projects such as clinical trials or the market entry of new drugs. BioPharma Credit's portfolio currently includes approximately 26 investments in various areas of the biopharmaceutical industry. The company works closely with experienced partners such as the pharmaceutical company Pharmakia or the analysis firm IHS to conduct comprehensive due diligence and carefully assess opportunities and risks. Another important element of BioPharma Credit's business model is the investors. Most of BioPharma Credit's investors are institutional investors such as pension funds or insurance companies. Therefore, the company also takes into account the needs and requirements of these investors in the selection of borrowers and projects. BioPharma Credit offers its investors high transparency and protection against potential risks. All investments are made through a GmbH structure with fixed terms and fixed interest payments. In addition, the portfolio is regularly monitored and adjusted by an expert team to minimize risks and seize opportunities. Overall, BioPharma Credit offers its investors an attractive opportunity to benefit from the opportunities in the rapidly growing biopharmaceutical market without directly entering the risks and challenges of the biopharmaceutical industry. At the same time, BioPharma Credit contributes to driving important innovations and advancements in medicine and thereby generating societal and health benefits. One of BioPharma Credit's most successful investments in recent years, for example, was a loan to the British biotechnology company Orchard Therapeutics. This company specializes in the development of gene therapies for rare diseases. The loan from BioPharma Credit helped Orchard Therapeutics conduct a clinical trial and enter the market. Orchard Therapeutics' gene therapy has since been approved by the European Medicines Agency and has the potential to improve the lives of millions of people worldwide. Overall, the success story of BioPharma Credit demonstrates how investments in the field of biopharmaceuticals and medicine can contribute to driving important innovations and advancements in medicine while also achieving attractive returns for investors. The company has established itself as an experienced and reliable partner that, thanks to its expertise and networks, will continue to identify and realize successful investments in the biopharmaceutical sector in the future. BioPharma Credit is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing BioPharma Credit's EBIT

BioPharma Credit's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of BioPharma Credit's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

BioPharma Credit's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in BioPharma Credit’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about BioPharma Credit stock

EBIT of BioPharma Credit is 129.85 M USD in 2025.

EBIT of BioPharma Credit changed from 122.18 M USD to 129.85 M USD, representing a 6.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT BioPharma Credit since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's BioPharma Credit historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioPharma Credit

All Key Metrics — BioPharma Credit